Business Context and Reporting Period
This Form 8-K is filed by Zafgen, Inc. (not Larimar Therapeutics, Inc.) on May 10, 2016. The report announces the financial results for the first quarter of 2016. The registrant is incorporated in Delaware with principal executive offices in Boston, Massachusetts.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It serves solely as a notification that Q1 2016 results have been announced.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, or specific risk factors. It includes a standard disclaimer stating that the information is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, limiting liability and incorporation by reference.
Investor Verification Checklist
- Verify the correct registrant name is Zafgen, Inc., as the input metadata incorrectly listed Larimar Therapeutics, Inc.
- Review Exhibit 99.1 (the press release) to obtain actual Q1 2016 financial figures.
- Confirm the specific date of the earliest event reported is May 10, 2016.
- Note that this 8-K is a notification of results, not a detailed financial statement itself.